Original Article

You have full text access to this OnlineOpen article

Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma†‡

  1. David J. Gallagher MD, BCH, BAO1,
  2. Matthew I. Milowsky MD1,2,
  3. Alexia Iasonos PhD3,
  4. Fernando C. Maluf MD1,
  5. Paul Russo MD4,
  6. Guido Dalbagni MD4,
  7. Machele S. Donat MD4,
  8. Mary G. Boyle RN1,
  9. Junting Zheng MS3,
  10. Jamie Riches BA1,
  11. Dean F. Bajorin MD1,2,§,*

Article first published online: 10 AUG 2009

DOI: 10.1002/cncr.24570

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5193–5201, 15 November 2009

Additional Information

How to Cite

Gallagher, D. J., Milowsky, M. I., Iasonos, A., Maluf, F. C., Russo, P., Dalbagni, G., Donat, M. S., Boyle, M. G., Zheng, J., Riches, J. and Bajorin, D. F. (2009), Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer, 115: 5193–5201. doi: 10.1002/cncr.24570

Author Information

  1. 1

    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Department of Medicine, Weill Medical College of Cornell University, New York, New York

  3. 3

    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

  4. 4

    Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

  1. §

    Fax: (212) 988-1079

*Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065

  1. †

    See related editorial on pages 5139-42, this issue.

  2. ‡

    Presented in part at the American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium; San Francisco, California; February 14-16, 2008.

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 10 AUG 2009
  3. Manuscript Accepted: 15 DEC 2008
  4. Manuscript Revised: 11 DEC 2008
  5. Manuscript Received: 28 AUG 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (209K)

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
    Direct Link:
  • 2
    Volkmer BG, Kuefer R, Bartsch G Jr, et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer. 2005; 104: 2384-2391.
    Direct Link:
  • 3
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 4
    Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165: 1111-1116.
  • 5
    Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999; 161: 1494-1497.
  • 6
    Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol. 1997; 158: 393-399.
  • 7
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927-1934.
  • 8
    [No authors listed] Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999; 354: 533-540.
  • 9
    Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group [see comments]. J Urol. 2008; 155: 1903-1906, 1996.
  • 10
    Hall RR; on behalf of the International Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, MRC Clinical Trials Unit, London, UK. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 178a. Abstract 710.
  • 11
    Winquist E. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171: 561-561.
  • 12
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48: 202-206.
  • 13
    Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145: 459-464; discussion.
  • 14
    Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J Urol. 1992; 148: 302-307.
  • 15
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer [see comments]. J Urol. 1996; 155: 495-499; discussion 499-500.
  • 16
    Studer U, Bacchi M, Biederman C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994; 152: 81-84.
  • 17
    Bono AV, Benvenuti C, Reali L, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res. 1989; 303: 533-540.
  • 18
    Cognetti F, Ruggeri EM, Felici A, et al; on behalf of the Study Group. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial [abstract]. J Clin Oncol. 2008; 26(May 20 suppl ). Abstract 5023.
  • 19
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol. 2005; 48: 189-201.
  • 20
    Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature. 1976; 264: 542-545.
  • 21
    Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986; 70: 163-169.
  • 22
    Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52: 134-141.
  • 23
    Nogue-Aliguer M, Carles J, Arrivi A, et al; Spanish Cooperative Group. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003; 97: 2180-2186.
    Direct Link:
  • 24
    Olivares J, Hyman W, Senzer N. A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC) [abstract]. J Clin Oncol. 2004; 22( 14S). Abstract 4590.
  • 25
    Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 2000; 18: 840-846.
  • 26
    Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007; 109: 549-555.
    Direct Link:
  • 27
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
  • 28
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 1431-1439.
  • 29
    Sternberg CN, de Mulder P, Schornagel JH, et al; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42: 50-54.
  • 30
    Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2008 Jul 14. [Epub ahead of print]
  • 31
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
  • 32
    Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC) [abstract]. J Clin Oncol. 2007; 25( 18S). Abstract 5080.
  • 33
    Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy [abstract]. Paper presented at the ASCO 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, Calif. Abstract 291.
  • 34
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
  • 35
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
  • 36
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
  • 37
    Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004; 22: 2781-2789.
  • 38
    Elting LS, Pettaway C, Bekele BN, et al. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer. 2005; 104: 975-984.
    Direct Link:
  • 39
    Joudi FN, Konety BR. Thee impact of provider volume on outcomes from urological cancer therapy. J Urol. 2005; 174: 432-438.
  • 40
    Dash A, Pettus JA, Bochner BH, et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC) [abstract]. J Clin Oncol. 2007; 25( 19S). Abstract 5077.
View Full Article (HTML) Get PDF (209K)